Dr. Dominick Angiolillo summarizes the results of the RE-DUAL PCI study showing the safety of dabigatran dual therapy post-PCI with doses approved for stroke prevention in AF. He also shows data on subgroup analysis in patients with ACS / no ACS as an index event and subgroup analysis looking at results dependent on the P2Y12 Inhibitor. Results of these subanalyses confirm the safety of dabigatran dual therapy in high risk patient populations.
New Insights Into Post-PCI Care: The Re-Dual PCI Study
May 9, 2019
Keep up to date with our latest
articles and journals